WHO Targets Rare Ebola Strain With Trial Recommendations

The World Health Organization (WHO) recently recommended prioritizing several experimental Bundibugyo Ebola treatments and vaccine candidates. This move addresses the ongoing outbreak in the Democratic Republic of the Congo and Uganda. Currently, no approved therapies or vaccines exist specifically for this rare viral strain. Consequently, the WHO urges researchers to evaluate these candidates in clinical trials.

Prioritizing Bundibugyo Ebola Treatments

Specifically, the advisory panels highlighted three therapeutic drugs for immediate evaluation. Therefore, clinical trials will focus on MBP134, maftivimab, and remdesivir. Additionally, the expert advisors recommended testing a combination therapy pairing a monoclonal antibody with remdesivir. Meanwhile, Regeneron has already positioned supplies of maftivimab on the ground in the DRC.

Preventive Interventions and Vaccine Candidates

Furthermore, for post-exposure prophylaxis, the WHO prioritizes Gilead’s experimental oral antiviral, obeldesivir. However, the success of this preventive treatment depends heavily on robust contact tracing. On the vaccine front, researchers are advancing two promising candidates.

First, the International AIDS Vaccine Initiative is developing a single-dose vaccine called rVSV Bundibugyo. Nevertheless, this candidate will likely require seven to nine months before trials begin. Second, Oxford University and the Serum Institute of India are developing the ChAdOx1 Bundibugyo vaccine. Importantly, this vaccine could enter clinical testing within two to three months.

In contrast, the WHO advised against using Merck’s licensed vaccine, Ervebo, outside of research settings. Specifically, existing evidence showing its cross-protection against the Bundibugyo strain remains inconclusive. Consequently, global health agencies are working together to design highly ethical clinical trials.

Frequently Asked Questions

Q1: What are the prioritized therapeutics for the Bundibugyo Ebola outbreak?

The WHO prioritized three experimental treatments: Mapp Biopharmaceutical’s MBP134, Regeneron’s maftivimab, and Gilead’s antiviral remdesivir. Additionally, experts recommend exploring a combination of a monoclonal antibody and remdesivir for those working in emergency medicine.

Q2: Is there a vaccine available for the Bundibugyo strain?

Currently, no approved vaccine exists specifically for the Bundibugyo strain of Ebola. However, candidates like ChAdOx1 Bundibugyo and rVSV Bundibugyo are currently in development and undergoing preparation for clinical trials.

References

1. WHO identifies Ebola treatments, vaccines be tested in trials amid outbreak – ETHealthworld
2. World Health Organization (WHO). Experts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus. May 28, 2026.
3. Regeneron Pharmaceuticals, Inc. Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak. May 28, 2026.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.